<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633490</url>
  </required_header>
  <id_info>
    <org_study_id>2007APA</org_study_id>
    <nct_id>NCT00633490</nct_id>
  </id_info>
  <brief_title>Study of Apatinib as an Inhibitor of Tumor Angiogenesis</brief_title>
  <official_title>Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor
      receptor (VEGFR), so it can inhibit tumor angiogenesis. This phase I study aims to determine
      the drug's toxicity and to find a dose level to be used in a phase II study in solid tumor
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apatinib is a tyrosin-inhibitor agent targeting at VEGFR (vasoendothelial growth factor
      receptor) to inhibit tumor angiogenesis. The anti-angiogenesis effect of apatinib has been
      viewed in preclinical tests (see protocol). This phase I clinical study is going to evaluate
      its toxicity and to find an appropriate dose level to be used in a phase II study in heavily
      treated solid tumor patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Anticipated">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity and tolerable dosage on the basis of NCI-CTCAE 3.0</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily</description>
    <arm_group_label>A</arm_group_label>
    <other_name>mesylate apatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 and ≤ 70 years of age

          -  Histological or cytological confirmed solid malignant tumor

          -  ECOG performance status of ≤ 2

          -  Standard regimen failed or no standard regimen available

          -  Life expectancy of more than 3 months

          -  Duration from the last therapy is more than 6 weeks for nitroso or mitomycin; more
             than 4 weeks for operation or radiotherapy; more than 4 weeks for cytotoxic agents or
             growth inhibitors.

          -  Laboratory values: hemoglobin ≥ 9.0g/dl, neutrophils ≥ 1.5×10^9/L, platelets ≥
             100×10^9/L , ALT ≤ 2.5 x upper limit of normal (ULN), AST ≤ 2.5 x ULN, serum bilirubin
             ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, PT,
             APTT, TT, Fbg normal

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Evidence of CNS metastasis

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix

          -  Intercurrence with one of the following: hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Receiving the therapy of thrombolysis or anticoagulation

          -  Abuse of alcohol or drugs

          -  Allergy to the ingredient of the agent or more than two kinds of food and drug

          -  Less than 4 weeks from the last clinical trial

          -  Disability of serious uncontrolled intercurrence infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, PhD</last_name>
    <email>jianggl@21cn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>July 21, 2008</last_update_submitted>
  <last_update_submitted_qc>July 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jin Li/Dr</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>Toxicity</keyword>
  <keyword>Efficacy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

